Back to Agenda
New Data and Insights on the Vendor Qualification Process in Drug Development
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development
Tufts University School of Medicine, United States
Review and panel discussion of the results from a new Tufts Center for the Study of Drug Development (TCSDD) Working Group study assessing the vendor qualification and selection process
Learning Objective : Discuss the prevailing approaches to vendor qualification in small, mid and large pharma organizations including the level of effort required and time taken; Describe the impact on drug development timelines; Recognize the point of view of clinical service providers from a time and cost standpoint; Identify how pharma companies and CROs are addressing qualification challenges.
Speaker(s)
Panelist
Tran Huynh
Fortrea, United States
Global Head, Clinical Vendor Strategy
Panelist
Patty Leuchten
Diligent Pharma, United States
Founder and CEO
Panelist
Neil McCullough
IQVIA, United States
Executive Vice President, Clinical Quality and Compliance
Panelist
Shyard Wong, DrMed
Sanofi, France
Global Head, Clinical Quality and Continuous Improvement
Have an account?